Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates

AUTOR(ES)

Milatovic, D.

FONTE

American Society for Microbiology

RESUMO

The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycylcycline exhibited excellent activity against all gram-positive cocci (MICs at which 90% of the isolates tested were inhibited [MIC90s], ≤1 μg/ml). In addition, it was also very potent against most members of the Enterobacteriaceae, with most MIC90s being ≤2 μg/ml. Among the nonfermenters, Acinetobacter spp. and Stenotrophomonas maltophilia are included in the in vitro spectrum of tigecycline activity.

Documentos Relacionados

• In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain
• In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates
• In Vitro Activities of Tigecycline (GAR-936) against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniae
• Activities of Tigecycline (GAR-936) against Legionella pneumophila In Vitro and in Guinea Pigs with L. pneumophila Pneumonia
• Activity of Tigecycline (GAR-936), a Novel Glycylcycline, against Enterococci in the Mouse Peritonitis Model